NPCM
HAE icon

North Peak Capital Management’s Haemonetics HAE Stock Holding History

North Peak Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.3M Sell
998,953
-104,039
-9% -$6.78M 9.36% 5
2025
Q4 		$88.4M Buy
1,102,992
+740,626
+204% +$49.8M 7.51% 6
2025
Q3 		$17.7M Buy
+362,366
New +$22.4M 1.55% 9

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

North Peak Capital Management's HAE Position: Q1 2026 in Review

North Peak Capital Management reduced its Haemonetics (HAE) stake by 9.4% in Q1 2026, selling an estimated $6.78M and leaving 998,953 shares worth $56.3M. The position accounts for 9.36% of the portfolio, ranked #5.

North Peak Capital Management first reported a position in HAE in Q3 2025 and has held it in 3 quarters since. The position peaked at $88.4M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • North Peak Capital Management held 998,953 shares of Haemonetics worth $56.3M as of Q1 2026.
  • North Peak Capital Management sold 104,039 Haemonetics shares in Q1 2026, an estimated $6.78M.
  • Haemonetics made up 9.36% of North Peak Capital Management's portfolio in Q1 2026, its #5 holding.
  • North Peak Capital Management first reported a position in Haemonetics in Q3 2025 and has held it in 3 quarters since.
  • North Peak Capital Management's Haemonetics position peaked at $88.4M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on North Peak Capital Management's 13F filing for Q1 2026, filed 14 May 2026.